COMP <GO>
ANGO vs JNJ // EV/EBITDA & P/E VALUATION
AngioDynamics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ANGO 1
— JNJ 9
■ METRIC PARITY
LAST: $12.35 (+1.81%) • MKT CAP: $519.4M
valuation
—
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANGO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANGO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 67.90% | -13.30 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.40% | 25.50% | -48.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.10% | 2.97% | -2.87 | JNJ | /fcf-yield <GO> |
| Operating Margin | -12.50% | 34.70% | -47.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -11.50% | 28.50% | -40.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 9.50% | 6.00% | +3.50 | ANGO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.12 | 5.59 | -3.47 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.4 | 62.1 | -22.69 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $519.4M | $662.49B | -$661.97B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANGO REV | JNJ REV | ANGO GROSS % | JNJ GROSS % | ANGO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $320.2M | $94.19B | 54.6% | 67.9% | $508.0K | $19.70B |
| FY 2024 | $292.5M | $88.82B | 53.9% | 69.1% | -$14.6M | $19.84B |
| FY 2023 | $303.9M | $85.16B | — | — | -$28.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANGO // BETA —
JNJ // BETA 1.08